Beijing Friendship Hospital, Capital Medical University
Beijing, Beijing Municipality, 101100, China
NCT Number: NCT07455240
The purpose of this study is to learn about:
* How PF-07328948 is changed and removed from the body after taking * Safety of PF-07328948 * The extent to which undesirable effects can be tolerated after taking PF-07328948 for the possible treatment of heart failure
This study is seeking participants who:
* Are healthy Chinese adults who are aged 18 years old and older * Have body mass index from 18.5 to under 28 kilograms/meter square * Have a total body weight over 50 kilograms (110 pounds) * Do not have a history of blood clots blocking an artery or vein
All participants in this study will receive oral daily PF-07328948 at the study clinic for 7 consecutive days.
The experiences of the participants receiving the study medicine will be looked at. This will help to see if the study medicine is safe.
Participants will take part in this study for around 10 weeks. During this time, participants will have 1 study visit at the study clinical and 1 contact over the phone.
Looking for future studies?
Notify Me18 year and older
All sexes
Interventional
Phase 1
Beijing, Beijing Municipality, 101100, China
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Oral tablet
Time frame: Day 1, 7
Time frame: Day 1, 7
Time frame: First dose through study completion, an average of 10 weeks
Pfizer
Industry
A Phase 1, Open-label Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of PF-07328948 Following Multiple Oral Doses in Healthy Chinese Adult Participants
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07130097
Healthy Participant
New Haven, Connecticut, United States
View Trial DetailsNCT07235137
COVID-19, Coronaviridae Infections
Shanghai, Shanghai Municipality, China
View Trial DetailsNCT06087055
Healthy Participant
Changchun, Jilin, China
View Trial DetailsNCT04962230
Healthy Participant
New Haven, Connecticut, United States
View Trial Details